Background: Polycystic ovary syndrome (PCOS) is the most frequent endocrine disorder seen in pre-menopausal women, affecting 5-10% of this population. It is characterized by menstrual irregularities and clinical hyperandrogenism such as hirsutism, seborrhoea and acne. PCOS women have insulin resistance, which results in compensatory hyperinsulinemia. A number of findings suggest that hyperinsulinemia may play a central role in the development of hyperandrogenism. This study is under taken to measure insulin resistance and leutenising hormone (LH) in PCOS patients and to see the relationship of insulin resistance with leutenising hormone (LH).Methods: Case control study was done taking 60 women PCOS and 60 age matched healthy women as controls. In all the subjects, concentrations of fasting plasma glucose estimated using enzymatic methods in semiautoanalyser. Fasting serum insulin and leutenising hormone (LH) measured by CLIA using Lumax-CLIA microplate reader. HOMA IR was calculated from estimated parameters.Results: The concentration of fasting serum insulin,fasting plasma glucose,HOMA –IR and leutenising hormone(LH) in controls are 9.33±3.08 µIU/ml,94.38±10.36mg/dl,12.16±0.67and 4.67±1.94 mIU/ml respectively; in PCOS cases they are 24.50±10.03µIU/ml,114.20±30.38 mg/dl,7.29±4.08 and 15.75±7.51 mIU/ml respectively. The mean concentrations of all the parameters were significantly (p value<0.05) increased in women with polycystic ovarian syndrome when compared with healthy women.Conclusions: This study shows that 75% of pcos women were insulin resistant and HOMA IR shows a positive correlation (r value 0.48, p<0.05) with serum leutenising hormone(LH).
Background: Diabetes mellitus is a chronic metabolic disorder that develops due to insulin deficiency or insulin resistance. Recent animal and human studies have reported bromocriptine to be effective in the management of type 2 diabetes mellitus. The present study was done to evaluate the antihyperglycemic effect of bromocriptine in dexamethasone induced hyperglycemic rats.Methods: Male wistar rats were used and divided into 5 groups. Dexamethosone was used to induce hyperglycemia in group B-E. Group A was the untreated control group, group B was the standard control group, group C was the oral 10 mg/kg of bromocriptine dissolved in 0.9% normal saline, group D was the oral 20 mg/kg metformin dissolved in 0.9% normal saline, group E was the oral 10 mg/kg bromocriptine+20 mg/kg metformin dissolved in 0.9% normal saline. Fasting blood glucose, post prandial blood glucose and body weight was estimated on day 1, 15, 30.Results: It was seen that dexamethasone induced hyperglycemia and increase in body weight in male wistar rats, which were significantly controlled by oral bromocriptine and bromocriptine with metformin combination.Conclusions: Results obtained from this study showed that bromocriptine can be a promising drug with novel mechanism to treat type 2 diabetes mellitus.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.